Static PDFs are so yesterday. With Adobe's new AI tools, they can transform into something far more useful in just a few clicks.
Easily create awesome AI slide decks with Gemini in NotebookLM, importing PDFs or Google Docs, pick a style and save hours of ...
XDA Developers on MSN
I ditched Notion, Trello, and Asana for this open-source app and it blew my mind
This open-source tool changed my workflow forever ...
Create AI-made presentations in using Claude projects, then refine in Cursor, and publish on a GitHub site for smooth ...
GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial ...
FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a ...
The presentation will be available on Nektar's website at http://www.nektar.com under Scientific Publications, following the formal presentation. The ongoing global ...
The abstract is currently available on the conference website, and the materials for the oral presentation will be available at www.monopartx.com on November 9, 2025. About Monopar Therapeutics Inc.
Abstract: Presentation Attack Detection (PAD) systems are usually designed independently of the fingerprint verification system. While this can be acceptable for use cases where specific user ...
Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED ...
- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ...
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results